A comparison of dequalinium chloride vaginal tablets (fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: A single-blind, randomized clinical trial of efficacy and safety fluomizin study group

Gynecologic and Obstetric Investigation

Volumn 73, Issue 1, 2012, Pages 8-15

  Weissenbacher, Ernst Rainer ^a   Donders, Gilbert ^b,c   Unzeitig, Vit ^f   Martinez De Tejada, Begoña ^d   Gerber, Stefan ^e   Halaška, Michael ^g   Špaček, Jiří ^h  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Regionaal Ziekenhuis Heilig Hart Tienen   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g Nemocnice Na Bulovce   (Czech Republic)

^h UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Bacterial vaginosis; Clindamycin; Dequalinium chloride; Fluomizin ; Local therapy; Pregnancy; Vaginal infections

Indexed keywords

CLINDAMYCIN; DEQUALINIUM; FLUOMIZIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINITIS; VULVOVAGINAL PRURITUS;

ADOLESCENT; ADULT; CANDIDIASIS, VULVOVAGINAL; CLINDAMYCIN; DEQUALINIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 84856120428     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000332398     Document Type: Article

References (30)

1. Sobel JD: Vaginitis. N Engl J Med 1997; 337: 1896-1903. (Pubitemid 28053998)
2. Forsum U, Holst E, Larsson PG, Vasquez A, Jakobsson T, Mattsby-Baltzer I: Bacterial vaginosis-a microbiological and immunological enigma. APMIS 2005; 113: 81-90. (Pubitemid 40343577)
3. Sobel JD: Bacterial vaginosis. Annu Rev Med 2000; 51: 349-356. (Pubitemid 30216042)
4. O'Brien RF: Bacterial vaginosis: many questions-any answers? Curr Opin Pediatr 2005; 17: 473-479.
5. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51: 1-78.
6. British Association for Sexual Health and HIV (BASHH), Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases): National guideline for the management of bacterial vaginosis (www.bashh.org/guidelines).
7. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK: High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193: 1478-1486. (Pubitemid 43794575)
8. Larsson PG, Forsum U: Bacterial vagino-sis-a disturbed bacterial flora and treatment enigma. APMIS 2005; 113: 305-316. (Pubitemid 40904299)
9. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J: Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41: 443-449.
10. Schmitt C, Sobel JD, Meriwether C: Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 1992; 79: 1020-1023.
11. Austin MN, Beigi RH, Meyn LA, Hillier SL: Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 2005; 43: 4492-4497. (Pubitemid 41298233)
12. Goldstein EJ, Citron DM, Cherubin CE, Hillier SL: Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993; 31: 363-372. (Pubitemid 23110676)
13. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT: In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis . Antimicrob Agents Chemother 2002; 46: 3995-3996. (Pubitemid 35403282)
14. Nagaraja P: Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol 2008; 26: 155-157. (Pubitemid 351652298)
15. DeBacker E, Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Temmerman M, Vaneechoutte M: Antibiotic susceptibility of Atopobium vaginae . BMC Infect Dis 2006; 6: 51.
16. D'Auria FD, Simonetti G, Strippoli V: Antimicrobial characteristics of a tincture of dequalinium chloride (in Italian). Ann Ig 1989; 1: 1227-1241.
17. Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G: Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung 2002; 52: 699-705.
18. Hugo WB, Frier M: Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol 1969; 17: 118-127.
19. Petersen EE, Weissenbacher ER, Hengst P, Spitzbart H, Weise W, Wolff F, Dreher E, Ernst U, Della Casa V, Pohlig G, Graf F, Kaiser RR: Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung 2002; 52: 706-715.
20. Strecker M, Kokemohr H, Teucher T, Schmitz H: Antiseptika gegen Vulvovaginitiden. TW Gynäkol 1993; 6: 409-412.
21. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach DA, Holmes KK: Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiological associations. Am J Med 1983; 74: 14-22. (Pubitemid 13221599)
22. Donders GG, Vereecken A, Dekeersmaecker A, van Bulck B, Spitz B: Wet mount microscopy reflects functional vaginal lactobacillary flora better than Gram stain. J Clin Pathol 2000; 53: 308-313.
23. Bauer P, Köhne K: Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029-1041.
24. Farrington CP, Manning G: Test statistics and sample size formulae for comparative binomial trials with null hypothesis of nonzero risk difference or non-unity relative risk. Stad Med 1990; 9: 1447-1454.
25. Mann H, Whitney D: On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist 1947; 50-60.
26. Donders GG: Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 2007; 21: 355-373. (Pubitemid 46838566)
27. Koumans EH, Markowitz LE, Hogan V: Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002; 35: S152-S172. (Pubitemid 35178327)
28. Agnew KJ, Hillier SL: The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis 1995; 22: 269-273.
29. Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S: Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 2008; 8: 3.
30. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G: The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005; 112: 234-240. (Pubitemid 40188254)